open access: Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

open access

Table 1. Patient, tumour and treatment characteristics of OC in BRCA1/2 patients with and without a history of BC

Histology:
Serous
Mucinous
Endometrioid
Clear cell
Undifferentiated
Adenocarcinoma
Other
Unknown

The results of this study underline the importance of offering
genetic testing to BC patients being at risk of BRCA1/2 mutation
carriership. Newly diagnosed mutation carriers can then be
informed about risk reducing salpingo-oophorectomy, which has
been associated with improved survival (Finch et al, 2014). Further,
we suggest that studies on survival in BRCA1/2-associated EOC
should stratify for BC history.